Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
New investigational targeted therapeutic, entrectinib, shows early promise

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.05.16
Views: 1844

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Alexander Drilon presents his research on entrectinib in a press release at AACR 2016.

Entrectinib, which targets the proteins TrkA/B/C, ROS1, and ALK, is reported as safe, tolerable, and showing signs of clinical activity in patients who had several different types of cancer with associated gene alterations.

For more on entrectinib, you can read the associated news article here or watch an interview with Dr Drilon here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation